<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445185</url>
  </required_header>
  <id_info>
    <org_study_id>HN015/HBV-EXT001</org_study_id>
    <nct_id>NCT00445185</nct_id>
  </id_info>
  <brief_title>Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™</brief_title>
  <official_title>A Study to Evaluate the Persistence of Anti-HBs Antibodies at Months 12, 24 and 36 in Pre-dialysis or Dialysis Patients Who Have Received a Primary Vaccination Course of Either Henogen's HBV Vaccine, HB-AS02V or GSK Biological's Fendrix™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current extension study will assess the persistence of anti-HBs antibodies at Months 12,
      24 and 36 after primary vaccination with Henogen's HBV vaccine or Fendrix™. This protocol
      posting deals with the objectives &amp; outcome measures of the extension phase at Months 12, 24
      and 36. The objectives &amp; outcome measures of the primary phase are presented in a separate
      protocol posting (NCT00291941).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who received complete full vaccination with Henogen HBV adjuvanted vaccine or
      Fendrix™ will participate in this persistence study for three long-term time points (12, 24
      and 36 months after the first dose of primary vaccination). Blood sampling will be done at
      each time point to measure immune persistence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-HBs antibody concentrations</measure>
    <time_frame>Months 12, 24 and 36.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of immune response</measure>
    <time_frame>Month 12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAEs retrospective reporting</measure>
    <time_frame>Month 12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RF-1 like antibody concentrations in the subset of subjects for whom this analysis was done at the primary study (HN014/HBV-001).</measure>
    <time_frame>Month 12, 24 and 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Henogen Hepatitis B vaccine for uremic patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fendrix hepatitis B vaccine for uremic patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Henogen HB vaccine</intervention_name>
    <description>Month 12, 24 and 36</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fendrix vaccine</intervention_name>
    <description>Month 12, 24 and 36</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained from the subject/ from the parent/ guardian of the
             subject.

          -  Subjects who completed the full course of primary vaccination.

        Exclusion Criteria:

          -  Immunosuppression caused by the administration of parenteral steroids or chemotherapy.

          -  Any confirmed or suspected human immunodeficiency virus (HIV) infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joëlle Nortier, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ULB Hôpital Erasme Département de Néphrologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>O.L.Vrouwziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RHMS La Madeleine ATH</name>
      <address>
        <city>Ath</city>
        <zip>7800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RHMS Clinique Louis Caty Baudour</name>
      <address>
        <city>Baudour</city>
        <zip>7331</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brugmann (site V Horta) Service de néphrologie</name>
      <address>
        <city>Bruxelles</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULB Hôpital Erasme Département de Néphrologie</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ -VUB Dienst Nefrologie</name>
      <address>
        <city>Bruxelles</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital civil de</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tivoli</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg Leuven Nierziekten</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Andre VESALE</name>
      <address>
        <city>Montigny Le Tilleul</city>
        <zip>6110</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RHMS TournayService de néphrologie</name>
      <address>
        <city>Tournai</city>
        <zip>7500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital JihlavaVrchlického</name>
      <address>
        <city>Jihlava</city>
        <zip>59586 33</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Hospital Liberec</name>
      <address>
        <city>Liberec</city>
        <zip>46063</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital with Outpatient Clinic Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Internal Medicine StrahovSermirska 5</name>
      <address>
        <city>Prague</city>
        <zip>169 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masaryk´s Hospital Socialni pece 3316/12A</name>
      <address>
        <city>Usti Nad Labem</city>
        <zip>401 13</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Rókus Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. István Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladár Teaching Hospital</name>
      <address>
        <city>Győr</city>
        <zip>9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pest County Flór Ferenc Hospital</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vas and Szombathely County Markusovszky Hospital</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2007</study_first_posted>
  <last_update_submitted>November 18, 2009</last_update_submitted>
  <last_update_submitted_qc>November 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Sophie Houard CSO</name_title>
    <organization>Henogen</organization>
  </responsible_party>
  <keyword>Dialysis</keyword>
  <keyword>Pre-dialysis</keyword>
  <keyword>Hepatitis B vaccine</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

